 Neoplasm Proteins
"Neoplasm Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
| Descriptor ID |
D009363
|
| MeSH Number(s) |
D12.776.624
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm Proteins".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm Proteins".
This graph shows the total number of publications written about "Neoplasm Proteins" by people in this website by year, and whether "Neoplasm Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 | | 1996 | 5 | 3 | 8 | | 1997 | 2 | 0 | 2 | | 1998 | 4 | 3 | 7 | | 1999 | 1 | 1 | 2 | | 2000 | 6 | 3 | 9 | | 2001 | 7 | 5 | 12 | | 2002 | 2 | 8 | 10 | | 2003 | 7 | 6 | 13 | | 2004 | 8 | 4 | 12 | | 2005 | 7 | 4 | 11 | | 2006 | 9 | 2 | 11 | | 2007 | 6 | 6 | 12 | | 2008 | 8 | 5 | 13 | | 2009 | 10 | 4 | 14 | | 2010 | 7 | 0 | 7 | | 2011 | 5 | 3 | 8 | | 2012 | 5 | 10 | 15 | | 2013 | 10 | 6 | 16 | | 2014 | 9 | 3 | 12 | | 2015 | 8 | 4 | 12 | | 2016 | 9 | 6 | 15 | | 2017 | 11 | 3 | 14 | | 2018 | 10 | 6 | 16 | | 2019 | 9 | 3 | 12 | | 2020 | 7 | 6 | 13 | | 2021 | 8 | 2 | 10 | | 2022 | 1 | 1 | 2 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 3 | 4 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasm Proteins" by people in Profiles.
-
Key AM, Earley EJ, Tzounakas VL, Anastasiadi AT, Nemkov T, Stephenson D, Dzieciatkowska M, Reisz JA, Keele GR, Deng X, Stone M, Kleinman S, Hansen KC, Norris PJ, Busch MP, Roubinian NH, Page GP, D'Alessandro A. Red blood cell urate levels are linked to hemolysis in vitro and post-transfusion as a function of donor sex, population and genetic polymorphisms in SLC2A9 and ABCG2. Transfusion. 2025 Mar; 65(3):560-574.
-
Lyu C, Vaddi PK, Elshafae S, Pradeep A, Ma D, Chen S. Unveiling RACK1: a key regulator of the PI3K/AKT pathway in prostate cancer development. Oncogene. 2025 Feb; 44(5):322-335.
-
Nielsen AJ, Albert GK, Sanchez A, Chen J, Liu J, Davalos AS, Geng D, Bradeen X, Hintzsche JD, Robinson W, McCarter M, Amato C, Tobin R, Couts K, Wilky BA, Davila E. DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors. J Clin Invest. 2024 Oct 22; 134(24).
-
Liu W, Cao H, Wang J, Elmusrati A, Han B, Chen W, Zhou P, Li X, Keysar S, Jimeno A, Wang CY. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma. Nat Commun. 2024 Aug 08; 15(1):6755.
-
Ha T, Morgan A, Bartos MN, Beatty K, Cogn? B, Braun D, Gerber CB, Gaspar H, Kopps AM, Rieubland C, Hurst ACE, Amor DJ, Nizon M, Pasquier L, Pfundt R, Reis A, Siu VM, Tessarech M, Thompson ML, Vincent M, de Vries BBA, Walsh MB, Wechsler SB, Zweier C, Schnur RE, Guillen Sacoto MJ, Margot H, Masotto B, Palafoll MIV, Nawaz U, Voineagu I, Slavotinek A. De novo variants predicting haploinsufficiency for DIP2C are associated with expressive speech delay. Am J Med Genet A. 2024 07; 194(7):e63559.
-
Le Guerrou? F, Bunker EN, Rosencrans WM, Nguyen JT, Basar MA, Werner A, Chou TF, Wang C, Youle RJ. TNIP1 inhibits selective autophagy via bipartite interaction with LC3/GABARAP and TAX1BP1. Mol Cell. 2023 03 16; 83(6):927-941.e8.
-
McCourt JL, Stearns-Reider KM, Mamsa H, Kannan P, Afsharinia MH, Shu C, Gibbs EM, Shin KM, Kurmangaliyev YZ, Schmitt LR, Hansen KC, Crosbie RH. Multi-omics analysis of sarcospan overexpression in mdx skeletal muscle reveals compensatory remodeling of cytoskeleton-matrix interactions that promote mechanotransduction pathways. Skelet Muscle. 2023 01 06; 13(1):1.
-
Washington C, Dapas M, Biddanda A, Magnaye KM, Aneas I, Helling BA, Szczesny B, Boorgula MP, Taub MA, Kenny E, Mathias RA, Barnes KC, Khurana Hershey GK, Kercsmar CM, Gereige JD, Makhija M, Gruchalla RS, Gill MA, Liu AH, Rastogi D, Busse W, Gergen PJ, Visness CM, Gold DR, Hartert T, Johnson CC, Lemanske RF, Martinez FD, Miller RL, Ownby D, Seroogy CM, Wright AL, Zoratti EM, Bacharier LB, Kattan M, O'Connor GT, Wood RA, Nobrega MA, Altman MC, Jackson DJ, Gern JE, McKennan CG, Ober C. African-specific alleles modify risk for asthma at the 17q12-q21 locus in African Americans. Genome Med. 2022 09 29; 14(1):112.
-
Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal A. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood. 2022 02 24; 139(8):1208-1221.
-
Wadugu BA, Nonavinkere Srivatsan S, Heard A, Alberti MO, Ndonwi M, Liu J, Grieb S, Bradley J, Shao J, Ahmed T, Shirai CL, Khanna A, Fei DL, Miller CA, Graubert TA, Walter MJ. U2af1 is a haplo-essential gene required for hematopoietic cancer cell survival in mice. J Clin Invest. 2021 11 01; 131(21).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|